Purpose: The purpose of this study was to retrospectively identify risk factors for postoperative pulmonary complications in patients undergoing elective abdominal aortic surgery via a midline incision.
Methods: We reviewed 181 consecutive patients who underwent operation between July 1986 to December 1992. Preoperative factors analyzed included age, sex, diabetes mellitus, history of smoking, chronic obstructive pulmonary disease, obesity, indication for surgery (aneurysm [126] or aortoiliac occlusive disease [AIOD] [55]), history of coronary artery disease, length of preoperative hospital stay, American Society of Anaesthesiologists class, and pulmonary function tests. Intraoperative factors analyzed included endotracheal tube diameter, percent of inspired oxygen, blood loss, blood and crystalloid replacement, total operative time, epidural analgesia, and stress ulcer prophylaxis.
Results: Although the operative mortality rate was only 1.7% (3 of 181), major pulmonary complications occurred in 29 (16%) patients, including two lung-related deaths. Pneumonia occurred in 17 (9%) patients, prolonged intubation greater than 24 hours occurred in nine (5%), and reintubation caused by pulmonary insufficiency occurred in three (2%). On univariate analysis, the following were associated with major pulmonary complications (p < 00.05): American Society of Anaesthesiologists class IV, age greater than 70 years, ideal body weight greater than 150%, forced vital capacity of 80% or less predicted, forced expiratory flow rate (25 to 75) of 60% or less predicted, crystalloid replacement greater than 6 L, and total operative time greater than 5 hours.
Conclusions: The presence of these pulmonary risk factors, notably increased age and weight, decreased forced vital capacity and forced expiratory flow rate (25 to 75), and expected prolonged operative time, influences our decision not to proceed with surgery for small aortic aneurysms or for AIOD causing claudication. Patients at high pulmonary risk with AIOD who require revascularization for limb salvage would be more likely to undergo extraanatomic bypass. Pulmonary risk factors may play as important a role as cardiac factors in elective aortic surgery.
Download full-text PDF |
Source |
---|
Cardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFBMJ Oncol
September 2023
Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Objective: This study aimed to explore the global burden of early-onset cancer based on the Global Burden of Disease (GBD) 2019 study for 29 cancers worldwid.
Methods And Analysis: Incidence, deaths, disability-adjusted life years (DALYs) and risk factors for 29 early-onset cancer groups were obtained from GBD.
Results: Global incidence of early-onset cancer increased by 79.
BMJ Oncol
September 2023
Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
Objective: Although adjuvant trastuzumab-based treatment (TBT) improves survival for patients with HER2-positive early invasive breast cancer (EIBC), risk of toxicity grows as patient age increases. We examined use of TBT and associated severe acute toxicity event (SATE) rates to understand the real-world impact.
Methods And Analysis: Women (50+ years), newly diagnosed with HER2-positive EIBC in England, 2014-2019, were identified from Cancer Registry data, linked to the Systemic Anti-Cancer Therapy dataset for TBT information.
BMJ Oncol
October 2023
MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK.
Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals free of the disease following treatment. Epidemiological studies demonstrate that cancer survivors are at an increased risk of cardiovascular disease (CVD), with cardiovascular (CV) mortality overtaking cancer mortality in some tumour types.
View Article and Find Full Text PDFTech Innov Patient Support Radiat Oncol
March 2025
Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
Background: Recent patient studies have linked higher immune cell doses with worse quality of life and survival. For thoracic radiotherapy, heart dose is a major contributor to the effective dose to immune cells (EDIC).
Purpose: This study investigates heart and immune cell doses for plans optimized using a cardiac-sparing knowledge-based planning (KBP) model and the impact of carefully crafted beam geometry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!